Sponsor Pipeline

Shanghai Allink Biotherapeutics Co., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
4
Active Trials
2
Recruiting
2
Disease Areas
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-08-03 NCT07742956 Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and… Phase 2 Not Yet Recruiting
Active Trials by Phase
Phase 2
2
Phase 1/2
1
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT07603791 Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and… NSCLC (Advanced Non-small Cell Lung Cancer) Not Yet Recruiting
NCT07742956 Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and… NSCLC (Advanced Non-small Cell Lung Cancer) Not Yet Recruiting
Phase 1/2
NCT06656390 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor… Advanced Cancer Recruiting
Phase 1
NCT06707610 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor… Advanced Cancer Recruiting
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (2) Lung Cancer (2)
Get alerts when Shanghai Allink Biotherapeutics Co., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free